Pharmaceutical company Viatris (NASDAQ:VTRS) is set to announce its second quarter earnings result on Thursday, before the opening bell. Wall Street expects the Pennsylvania-based drugmaker to post ...

Pantry Plus More’s annual Back to School Bash takes a year’s worth of work to pull together. Thousands of hours volunteered ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

On a turf field in Morgantown, West Virginia, last week, mine rescue teams from across the state put their training to use as ...

Mylan CEO Heather Bresch was called to testify before Congress last year about the huge price increase for the life-saving allergy medicine to $600. After the controversy, the company cut the list ...

Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...

Mylan's generic version will hit shelves within several weeks at a list price of $300 for a two-pack carton in dosages of either 0.15 milligrams or 0.30 mg, the company said.

Mylan has agreed to buy certain women’s health-care businesses from India’s Famy Care Ltd. for $750 million in cash, in a move that will position Mylan as a leading provider of contraceptives ...

Mylan NV, whose price increases on its lifesaving EpiPen drug drew broad criticism this month, said Monday it would launch a half-priced generic version of the medicine—in effect, competing ...

Mylan has priced the EpiPen to recover the company’s investment in the product, she told the newspaper. But even her own father, a U.S. senator, has weighed in on the onslaught of criticism over ...

Mylan made $100 in profit on an EpiPen two-pack, its CEO said. But that number presumes Mylan paid taxes far higher than its actual U.S. tax rate, which specialists have pegged at nearly zero.

Drugmaker Mylan is launching a generic version of its own EpiPen. The lower price could quiet criticism about the high cost of the brand-name anti-allergy drug. There's also a business twist.